Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background Targeting higher hemoglobin with erythropoiesis-stimulating agents (ESAs) to treat anemia of chronic kidney disease (CKD) is associated with increased cardiovascular risk. Study Design Meta-regression analysis examining the association of ESA dose with adverse outcomes, independent of target or achieved hemoglobin. Setting and Population Patients with anemia of CKD, irrespective of dialysis status. Selection Criteria for Studies We searched MEDLINE (inception to August 2010) and bibliographies of published meta-analyses and selected randomized controlled trials assessing the efficacy of ESAs for treatment of anemia in adults with CKD, with minimum 3-month duration. Two authors independently screened citations and extracted relevant data. Individual study arms were treated as cohorts and constituted the unit of analysis. Predictors ESA dose standardized to a weekly epoetin alfa equivalent, and hemoglobin levels. Outcomes All-cause and cardiovascular mortality, cardiovascular events, kidney disease progression or transfusion requirement. Results 31 trials (12,956 patients) met criteria. All-cause mortality was associated with higher (per epoetin-alfa–equivalent 10,000-U/wk increment) first-3-month mean ESA dose (incidence rate ratio [IRR], 1.42; 95% CI, 1.10–1.83) and higher total-study-period mean ESA dose (IRR, 1.09; 95% CI, 1.02–1.18). First-3-month ESA dose remained significant after adjusting for first-3-month mean hemoglobin (IRR, 1.48; 95% CI, 1.02- 2.14), as did total-study-period mean ESA dose adjusting for target hemoglobin (IRR, 2 1.41; 95% CI, 1.08–1.82). Parameter estimates between ESA dose and cardiovascular mortality were similar in magnitude and direction but not statistically significant. Higher total-study-period mean ESA dose was also associated with increased rate of hypertension, stroke, and thrombotic events including dialysis vascular access-related thrombotic events. Limitations use of study-level aggregated data; use of epoetin alfa–equivalent doses; lack of adjustment for confounders. Conclusions In patients with CKD, higher ESA dose might be associated with all-cause mortality and cardiovascular complications independent of hemoglobin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating the mean and variance from the median, range, and the size of a sample
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-13 · Cited by 9,062
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Improved tests for a random effects meta‐regression with a single covariate
Knapp, G., & Hartung, J. (2003) · Statistics in Medicine · doi:10.1002/sim.1482 · Cited by 2,075 · cited 1×
“For the annualized change in GFR, we fit random-effects variance-weighted metaregressions.(26) The GFR analysis is re-”
MethodBesarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Anthropometric Reference Data for Children and Adults: United States, 2003-2006: (623932009-001)
McDowell, M. A., Fryar, C. D., Ogden, C. L., & Flegal, K. M. (2008) · PsycEXTRA Dataset · doi:10.1037/e623932009-001 · Cited by 1,378
Recombinant Human Erythropoietin in the Treatment of Acute Ischemic Stroke
Ehrenreich, H., Weissenborn, K., Prange, H., Schneider, D., Weimar, C., Wartenberg, K., Schellinger, P. D., Bohn, M., Becker, H., Wegrzyn, M., et al. (2009) · Stroke · doi:10.1161/strokeaha.109.564872 · Cited by 605
Mechanism of erythropoietin-induced hypertension
Vaziri, N. D. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70413-0 · Cited by 154
Cited by
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure
Ortiz, A., Covic, A., Fliser, D., Fouque, D., Goldsmith, D., Kanbay, M., Mallamaci, F., Massy, Z. A., Rossignol, P., Vanholder, R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60384-6 · Cited by 435
Flamme, I., Oehme, F., Ellinghaus, P., Jeske, M., Keldenich, J., & Thuss, U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111838 · Cited by 170
“Thus, the abnormally high peak concentrations typically associated with standard rhEPO therapy, which may impact on the long-term safety of treatment [3,50], might be avoided by therapy with BAY 85-3934.”
Background
Metadata
- Authors
- Koulouridis, I., Alfayez, M., Trikalinos, T. A., Balk, E. M., & Jaber, B. L.
- Venue
- American Journal of Kidney Diseases
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 61
- Issue
- 1
- Pages
- 44-56
- ISSN
- 0272-6386 (ISSN-L)
- OpenAlex
- W2023900607
- Cited by
- 203
- References
- 8
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis. https://app.cochat.ai/papers/10.1053/j.ajkd.2012.07.014
- The paper
- Koulouridis, I., Alfayez, M., Trikalinos, T. A., Balk, E. M., & Jaber, B. L. (2013). Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2012.07.014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.